Search | Clinical Trials Finder

Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions: Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 38
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 13
States / cities: Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Placebo, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 15
States / cities: Bakersfield, California • Beverly Hills, California • Stamford, Connecticut + 12 more

Conditions: Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: PEGylated recombinant human hyaluronidase PH20, Docetaxel; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Encinitas, California • Fresno, California • San Diego, California + 5 more

Conditions: Stomatitis
Interventions: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 35 more

Conditions: Solid Tumors
Interventions: DF6002, Nivolumab; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 21
States / cities: Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more

Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: enfortumab vedotin, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 29
States / cities: Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more

Conditions: Lung Cancer
Interventions: Erlotinib, SBRT; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Dallas, Texas

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Orange, California + 10 more

Conditions: Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions: RNDO-564, Pembrolizumab; Drug
Lead sponsor: Rondo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more

Conditions: Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
Interventions: TAK-186; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Locally Advanced or Metastatic NSCLC
Interventions: PBF-1129; Drug
Lead sponsor: Palobiofarma SL; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
Interventions: Atezolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed; Drug
Lead sponsor: BlossomHill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Telisotuzumab Adizutecan, Standard of Care, Osimertinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 13 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: GSK1120212, docetaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 25
States / cities: Scottsdale, Arizona • Orange, California • Aurora, Colorado + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: ZD6474, Placebo, ZD1839; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 18
States / cities: Pine Bluff, Arkansas • Los Angeles, California • Palm Springs, California + 15 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Osimertinib, Lazertinib, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,074 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 20
States / cities: Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more

Conditions: Cancer
Interventions: SRK-181, anti-PD-(L)1 antibody therapy; Biological
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Fullerton, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Zidesamtinib (NVL-520); Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 20
States / cities: Orange, California • Palo Alto, California • Sacramento, California + 15 more

Search by objective public record fields.

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

A Study of DF6002 Alone and in Combination With Nivolumab

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

PBF-1129 in Patients With NSCLC

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)